Core Insights - Cytek Biosciences reported a record fourth-quarter revenue of $62.1 million, representing an 8% year-over-year increase, attributed to stabilization in the U.S., growth in the E.U., and strong performance in APAC [3][6] - The company ended 2025 with a net loss of $44.1 million, which included a significant non-cash deferred tax valuation allowance [5][13] - Cytek initiated 2026 revenue guidance of $205–212 million, assuming improved market conditions in EMEA and the U.S., along with continued growth in service and reagents [4][16] Revenue Growth - EMEA revenue grew 21% in Q4, driven by services and instruments for academic and government customers, while U.S. revenue grew 5% with double-digit service revenue growth [1][2] - The company experienced double-digit year-over-year revenue growth in both EMEA and APAC during Q4, with mid-single-digit growth in the U.S. [2] Profitability and Margins - GAAP gross margin fell to 53% in Q4, down from 59% a year earlier, attributed to higher costs in service and product gross margins [11] - Adjusted EBITDA for 2025 declined to $5.0 million from $22.4 million in the previous year [5][14] Installed Base and Product Performance - Cytek expanded its global installed base by 208 instruments in Q4, ending 2025 with 3,664 units installed [7] - The launch of the Cytek Aurora Evo system contributed to a 21% unit growth in the Aurora category in Q4 [7] Recurring Revenue and Reagents - Recurring revenue represented 34% of total revenue for 2025, increasing 21% year-over-year [9] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year, driven by initiatives such as faster delivery times and a larger catalog [8] Cash Position and Share Buybacks - Cytek ended 2025 with $261.5 million in cash and equivalents, with a slight negative free cash flow of -$0.2 million in Q4 [15] - The company repurchased approximately $15.1 million of stock during 2025, representing about 3.3 million shares [15] Future Outlook - The company expects continued strong growth in service and reagents but anticipates only modest growth in instruments [17] - Management plans to invest commercially in segments where the company is currently weak, including enhancements to the reagent sales force [17]

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q4 and full year 2025 on February 26, 2026, with a conference call to discuss the results and outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution, high-content, and high-sensitivity cell analysis [2]. - The company's product offerings include core FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Aurora™ Evo systems, as well as the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [2]. - Cytek is headquartered in Fremont, California, and has a global presence with offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with the exception of the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [3]. Information Distribution - Cytek utilizes various channels, including its website, LinkedIn page, and X account, to distribute information about the company, products, and financial announcements, complying with Regulation FD [4].

Core Insights - Cytek Biosciences, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close, followed by a conference call to discuss the results and outlook [1] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2] - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents and software, providing a comprehensive suite of solutions for customers [2] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2] Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3] Information Distribution - The company utilizes multiple channels, including its website, LinkedIn, and X account, to disseminate material information and comply with disclosure obligations under Regulation FD [4]

Core Insights - Cytek Biosciences has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District, reflecting its commitment to the EMEA region and enhancing service for customers [1][4] - The new site has increased the company's footprint by over 40% and includes a dedicated customer service and training center, providing hands-on training for researchers [2] - The success of Cytek's reagent business is a major driver for this expansion, with the company transitioning warehouse operations in-house to improve operational efficiency and quality control [3] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [5] - The company's product offerings include various systems and technologies designed to enhance multiplexing capabilities and provide comprehensive solutions for researchers [5] - Cytek's products are primarily for research use, with certain systems available for clinical use in specific regions [6] Strategic Importance - Europe is identified as a key region for Cytek's global growth, and the new Amsterdam facility is expected to enhance the company's capabilities in delivering solutions and services across the EMEA region [4][15] - The expansion aims to support scientific understanding and accelerate data-driven decision-making, fostering innovation within the industry [4]

Core Viewpoint - Cytek Biosciences, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating its active engagement in the healthcare investment community [1]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that specializes in high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [3]. - The company offers a comprehensive suite of products including the Cytek Aurora™, Northern Lights™, and Cytek Orion™ systems, as well as flow cytometers and imaging products under the Amnis and Guava brands [3]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [3]. Upcoming Events - Cytek management is scheduled for a fireside chat on June 11 at 11:40 a.m. Pacific Time, which will be accessible via a live and archived webcast on the company's website [2].